Application of ABC transporter C4 inhibitor in preparation of medicine for treating breast cancer

By developing ABC transporter C4 inhibitor combined with pyrrolitinib, the problem of pyrrolitinib resistance in HER2-positive breast cancer patients has been solved, significantly reducing the proliferation ability of breast cancer cells, and providing new therapeutic strategies and targets. Extends the patient's survival.

CN118976110APending Publication Date: 2024-11-19JIANGSU INST OF NUCLEAR MEDICINE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411079099.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Patients with HER2-positive breast cancer are prone to acquired resistance after receiving pyrrolitinib, resulting in a weakening of the treatment effect. There is currently a lack of effective strategies to overcome this resistance, especially regarding the ABC transporter C4 in this process. The regulatory mechanism has not been studied.

Method used

Developed ABC transporter C4 inhibitors, including siRNAs that target ABC transporter C4, antibodies against ABC transporter C4, and small-molecule compounds that inhibit ABC transporter C4 expression, combined with pyrrolitinib to reverse breast cancer cell pairs Drug resistance.

Benefits of technology

By reducing the expression of ABC transporter C4, the proliferation ability of HER2-positive breast cancer cells is significantly reduced and the number of apoptotic cells is increased, effectively reversing drug resistance, providing new targets and therapeutic strategies to prolong patient survival.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976110A_ABST
    Figure CN118976110A_ABST
Patent Text Reader

Abstract

The invention relates to application of an ABC transporter C4 inhibitor in preparation of a medicine for treating breast cancer, and belongs to the technical field of biological medicine. The invention provides application of an ABC transporter C4 inhibitor in preparation of a medicine for preventing and / or treating breast cancer. In-vivo and in-vitro experiments show that knock-down of the expression of the ABC transporter C4 can effectively reverse the drug-resistant activity of HER2 positive breast cancer cells to pyrrotinib (specifically, compared with breast cancer HER2 positive breast cancer cells without knock-down of the expression of the ABC transporter C4, the drug-resistant activity of the HER2 positive breast cancer cells to the pyrrotinib can be effectively reversed; the proliferation capacity of breast cancer HER2 positive breast cancer cells with knockdown ABC transporter C4 expression is remarkably reduced and the apoptosis quantity is remarkably increased after the breast cancer HER2 positive breast cancer cells are intervened by the pyrrotinib). Therefore, the ABC transporter C4 can be used as a new target spot for preventing and treating the breast cancer, and the ABC transporter C4 inhibitor has great application prospects in preparation of medicines for preventing and / or treating the breast cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to application of an ABC transporter protein C4 inhibitor in preparing a medicine for treating breast cancer, and belongs to the technical field of biomedicine. Background Art

[0002] Breast cancer is a malignant tumor that originates from the mammary epithelium. Human epidermal growth factor receptor-2 (HER2)-positive breast cancer is a very important type of breast cancer, accounting for about 20-30%. This type of breast cancer is usually insensitive to endocrine therapy, but sensitive to targeted drug therapy. With the continuous development of anti-HER2 targeted drugs, the survival of patients with this type of breast cancer has been significantly improved. At present, a variety of anti-HER2 targeted drugs have been proven to play a role in the treatment of HER2-positive breast cancer, such as small molecule kinase inhibitors, monoclonal antibodies, and antibody-drug conjugates (ADCs). Pyrotinib is one of the HER2-targeted small molecule kinase inhibitors and is widely used in the treatment of HER2-positive recurrent or metastatic breast cancer patients.

[0003] Although targeted drug therapy based on pyrotinib can improve the overall survival (OS) of some HER2-positive breast cancer patients, its secondary acquired resistance is an important factor affecting the prognosis of patients. Acquired resistance can seriously weaken or eliminate the therapeutic effect of pyrotinib on HER2-positive breast cancer. Under the pressure of long-term treatment with pyrotinib, some HER2-positive breast cancer cells may develop acquired resistance through mechanisms such as mutation of the HER2 kinase domain, abnormal amplification of the HER2 gene, activation of the tyrosine kinase receptor bypass pathway, and activation of the drug efflux system. Therefore, it is of great clinical significance to deeply understand the mechanism of acquired resistance of pyrotinib to HER2-positive breast cancer and find a strategy to overcome the pyrotinib resistance in HER2-positive breast cancer, which is of great clinical significance for prolonging the survival of HER2-positive breast cancer patients. ABC transporter C4 (Recombinant ATP Binding Cassette Transporter C4, ABCC4) is an important membrane transporter protein belonging to the ABCC subfamily of ABC transporters. It plays a key role in many physiological and pathological processes. At present, there are no reports on the research on the regulation of ABC transporter C4 on the resistance activity of HER2-positive breast cancer cells to pyrotinib. Summary of the invention

[0004] To solve the above problems, the present invention provides the use of an ABC transporter C4 (ABCC4) inhibitor in the preparation of a drug for preventing and / or treating breast cancer. An ABC transporter C4 inhibitor refers to an inhibitor that inhibits the expression of ABC transporter C4 in cells.

[0005] In one embodiment of the present invention, the prevention and / or treatment of breast cancer includes reversing the drug resistance activity of breast cancer cells to pyrotinib.

[0006] In one embodiment of the present invention, the breast cancer cells include HER2-positive breast cancer cells; the HER2-positive breast cancer cells include HER2-positive breast cancer cells that are resistant to pyrotinib.

[0007] In one embodiment of the present invention, the HER2-positive breast cancer cells include SKBR-3 cell line, MDA-MB-453 cell line, HCC419 cell line and / or BT474 cell line.

[0008] In one embodiment of the present invention, the ABC transporter C4 inhibitor includes siRNA targeting the gene encoding ABC transporter C4, an antibody against ABC transporter C4 and / or a small molecule compound that inhibits the expression of ABC transporter C4.

[0009] In one embodiment of the present invention, the anti-ABC transporter C4 antibody includes an anti-ABC transporter C4 monoclonal antibody and / or an anti-ABC transporter C4 polyclonal antibody.

[0010] In one embodiment of the present invention, the composition of the drug comprises an ABC transporter C4 inhibitor and pyrotinib.

[0011] In one embodiment of the present invention, the composition of the drug further comprises a pharmaceutically acceptable excipient.

[0012] In one embodiment of the present invention, the pharmaceutically acceptable excipients include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids and / or release retardants.

[0013] In one embodiment of the present invention, the dosage form of the drug is powder, tablet, granule, capsule, solution, emulsion, suspension, aerosol, ointment, suppository, lotion or injection.

[0014] The present invention also provides a drug for preventing and / or treating breast cancer, wherein the drug comprises an ABC transporter protein C4 inhibitor.

[0015] In one embodiment of the present invention, the prevention and / or treatment of breast cancer includes reversing the drug resistance activity of breast cancer cells to pyrotinib.

[0016] In one embodiment of the present invention, the breast cancer cells include HER2-positive breast cancer cells; the HER2-positive breast cancer cells include HER2-positive breast cancer cells that are resistant to pyrotinib.

[0017] In one embodiment of the present invention, the HER2-positive breast cancer cells include SKBR-3 cell line, MDA-MB-453 cell line, HCC419 cell line and / or BT474 cell line.

[0018] In one embodiment of the present invention, the ABC transporter C4 inhibitor includes siRNA targeting the gene encoding ABC transporter C4, an antibody against ABC transporter C4 and / or a small molecule compound that inhibits the expression of ABC transporter C4.

[0019] In one embodiment of the present invention, the anti-ABC transporter C4 antibody includes an anti-ABC transporter C4 monoclonal antibody and / or an anti-ABC transporter C4 polyclonal antibody.

[0020] In one embodiment of the present invention, the composition of the drug comprises an ABC transporter C4 inhibitor and pyrotinib.

[0021] In one embodiment of the present invention, the composition of the drug further comprises a pharmaceutically acceptable excipient.

[0022] In one embodiment of the present invention, the pharmaceutically acceptable excipients include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids and / or release retardants.

[0023] In one embodiment of the present invention, the dosage form of the drug is powder, tablet, granule, capsule, solution, emulsion, suspension, aerosol, ointment, suppository, lotion or injection.

[0024] The present invention also provides a molecular marker for diagnosing pyrotinib resistance of breast cancer cells, wherein the molecular marker comprises ABC transporter protein C4 and / or a gene encoding ABC transporter protein C4.

[0025] In one embodiment of the present invention, the breast cancer cells include HER2-positive breast cancer cells; the HER2-positive breast cancer cells include HER2-positive breast cancer cells that are resistant to pyrotinib.

[0026] In one embodiment of the present invention, the HER2-positive breast cancer cells include SKBR-3 cell line, MDA-MB-453 cell line, HCC419 cell line and / or BT474 cell line.

[0027] The present invention also provides the use of a reagent for detecting the above molecular marker in a sample to be tested in the preparation of a product for diagnosing pyrotinib resistance of breast cancer cells.

[0028] In one embodiment of the present invention, the breast cancer cells include HER2-positive breast cancer cells; the HER2-positive breast cancer cells include HER2-positive breast cancer cells that are resistant to pyrotinib.

[0029] In one embodiment of the present invention, the HER2-positive breast cancer cells include SKBR-3 cell line, MDA-MB-453 cell line, HCC419 cell line and / or BT474 cell line.

[0030] In one embodiment of the present invention, the product comprises a detection kit.

[0031] The present invention also provides a product for diagnosing pyrotinib resistance of breast cancer cells, the product comprising a reagent for detecting the above molecular marker in a sample to be tested.

[0032] In one embodiment of the present invention, the breast cancer cells include HER2-positive breast cancer cells; the HER2-positive breast cancer cells include HER2-positive breast cancer cells that are resistant to pyrotinib.

[0033] In one embodiment of the present invention, the HER2-positive breast cancer cells include SKBR-3 cell line, MDA-MB-453 cell line, HCC419 cell line and / or BT474 cell line.

[0034] In one embodiment of the present invention, the product comprises a detection kit.

[0035] The technical solution of the present invention has the following advantages:

[0036] 1. The present invention provides the use of ABC transporter C4 inhibitors in the preparation of drugs for preventing and / or treating breast cancer. In vivo and in vitro experiments show that knocking down the expression of ABC transporter C4 can effectively reverse the drug resistance of HER2-positive breast cancer cells to pyrotinib (specifically, compared with breast cancer HER2-positive breast cancer cells in which the expression of ABC transporter C4 is not knocked down, the proliferation ability of breast cancer HER2-positive breast cancer cells in which the expression of ABC transporter C4 is knocked down after intervention with pyrotinib is significantly decreased and the number of apoptosis is significantly increased). Therefore, ABC transporter C4 can be used as a new target for the prevention and treatment of breast cancer, especially HER2-positive breast cancer, and ABC transporter C4 inhibitors have great application prospects in the preparation of drugs for preventing and / or treating breast cancer, especially HER2-positive breast cancer.

[0037] 2. The present invention provides the use of a reagent for detecting the level of ABC transporter C4 in a sample to be tested in the preparation of a product for diagnosing pyrotinib resistance in breast cancer cells. Studies have shown that ABC transporter C4 is highly expressed in HER2-positive breast cancer cells that are resistant to pyrotinib. Therefore, ABC transporter C4 can be used as a molecular marker for the preparation of a product (e.g., a detection kit) for diagnosing pyrotinib resistance in breast cancer cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 :Effects of different concentrations of pyrotinib on the proliferation activity of parental cells SKBR-3 and pyrotinib-resistant cells SKBR-3_PR. Figure 1 A: Morphological differences between parental cells SKBR-3 and pyrotinib-resistant cells SKBR-3_PR; B: Pyrotinib inhibits the proliferation and IC of SKBR-3 and SKBR-3_PR cells 50 Test results: The concentration range of pyrotinib was 0-100 μmol / L, and the treatment time was 24 hours. ** P<0.01, *** P<0.001.

[0039] Figure 2 : Expression of ABCC4 at transcriptional and protein levels in parental cells SKBR-3 and pyrotinib-resistant cells SKBR-3_PR. Figure 2 A: mRNA expression of ABCC4 in parental cells SKBR-3 and pyrotinib-resistant cells SKBR-3_PR; B: protein expression of ABCC4 in parental cells SKBR-3 and pyrotinib-resistant cells SKBR-3_PR, GAPDH was used as the internal reference protein. *** P<0.001.

[0040] Figure 3: Effect of pyrotinib on the proliferation activity of drug-resistant cells SKBR-3_PR after knockdown of ABCC4. Figure 3 A: ABCC4 protein expression in pyrotinib-resistant SKBR-3_PR cells after transfection with ABCC4 shRNA, GAPDH as internal reference protein; B: Pyrotinib inhibits SKBR-3_PR cell proliferation and IC before and after ABCC4 knockdown 50 Test results: The concentration range of pyrotinib was 0-180 μmol / L, and the treatment time was 24 hours. ** P<0.01, *** P<0.001.

[0041] Figure 4 : Evaluation of the therapeutic effect of pyrotinib in tumor-bearing mice. Figure 4 Middle, A: parental cells SKBR-3, pyrotinib-resistant cells SKBR-3_PR, and ABCC4 knockdown-resistant cells SKBR-3_PR ABCC4 KD A: Fluorescence imaging of tumors in tumor-bearing mice after 14 days of treatment with pyrotinib (15 mg / kg); B: changes in body weight of mice in each group; C: growth trend of tumor volume; D: expression of Ki67 and number of apoptotic cells in tumor tissues of each group. *** P<0.001. DETAILED DESCRIPTION

[0042] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

[0043] If no specific experimental steps or conditions are specified in the following examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be purchased commercially.

[0044] Experimental Example 1: Relationship between ABC transporter C4 levels and pyrotinib resistance in HER2-positive breast cancer cells

[0045] 1. Construction of HER2-positive breast cancer cell lines resistant to pyrotinib

[0046] SKBR-3 cells (purchased from Wuhan Pronocell Life Science Co., Ltd.) were cultured at 1×10 7After the inoculum of 100 μg / ml was inoculated into a T25 culture flask supplemented with 5 mL of RPMI-1640 medium (purchased from Sigma) containing 10% (v / v) fetal bovine serum (purchased from Gibco), the cells were cultured in a cell culture incubator at 37°C and 5% (v / v) CO2 for 24 h. After 24 h of culture, SKBR-3 cells were intervened with pyrotinib, and the intervention process was as follows:

[0047] The medium in the T25 culture flask was removed by pouring off, and the cells in the T25 culture flask were washed with phosphate buffer (purchased from Bio-Technology Co., Ltd.), and 5 mL of DMEM medium (purchased from Thermo Fisher Scientific) containing 0.5 μM pyrotinib (purchased from MedChemExpress (MCE)) was added. Inc.) was added to a T25 culture flask and cultured in a cell culture incubator at 37°C and 5% (v / v) CO2 for 24 hours; after culturing for 24 hours, the culture medium in the T25 culture flask was dumped out, the cells in the T25 culture flask were rinsed with phosphate buffer, and 5 mL of DMEM culture medium without pyrotinib was added to the T25 culture flask, and cultured in a cell culture incubator at 37°C and 5% (v / v) CO2 for 7 days; after culturing for 7 days, the culture medium in the T25 culture flask was dumped out, the cells in the T25 culture flask were rinsed with phosphate buffer, and 5 mL of DMEM culture medium containing 1 μM pyrotinib was added to the T25 culture flask, and cultured in a cell culture incubator at 37°C and 5% (v / v) CO2 for 24 hours; the above steps were repeated until the cell density in the T25 culture flask reached 90%, completing the first stage of intervention;

[0048] After the first stage of intervention, the cells in the T25 culture flask were passaged into new T25 culture flasks, and the intervention concentration of pyrotinib was continuously increased by referring to the operation of the first stage of intervention until the cell growth state and shape were finally stable, and the pyrotinib-resistant SKBR-3 cell line SKBR-3_PR was obtained (the pyrotinib-resistant SKBR-3 cell line SKBR-3_PR was obtained through three stages of intervention, with 0.5μM and 1μM pyrotinib used in the first stage of intervention, 1μM and 2μM pyrotinib used in the second stage of intervention, and 2μM and 5μM pyrotinib used in the third stage of intervention).

[0049] 2. Detection of the sensitivity of SKBR-3 and SKBR-3_PR cells to pyrotinib

[0050] The cell morphology of SKBR-3 cells and SKBR-3_PR cells obtained in Example was observed using an inverted microscope. The observation results are shown in Figure 1 A. SKBR-3 cells and SKBR-3_PR cells were cultured at 1×10 4The cells were inoculated into 96-well plates with 100 μL of RPMI-1640 medium containing 10% (v / v) fetal bovine serum per well, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 h. After 24 h of culture, 100 μL of cells containing different concentrations (0 μM, 3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM, with 6 replicate wells for each concentration) were added. Pyrotinib DMEM medium was added to the wells of SKBR-3 cells and SKBR-3_PR cells, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 h; after 24 h of culture, MTT reagent (purchased from Bio-Tech) was added to the 96-well plate at an amount of 20 μL per well, and incubated at 37°C in the dark for 4 h; the OD value of each group was detected at a wavelength of 490 nm using an ELISA reader, and the cell survival rate was calculated. The experimental results are shown in Figure 1 B in the figure; the calculation formula for cell survival rate is as follows:

[0051] Cell survival rate (%) = [(OD value of experimental group - OD value of blank group) / (OD value of control group - OD value of blank group)] × 100%.

[0052] like Figure 1 As shown in A, the boundaries of pyrotinib-resistant SKBR-3_PR cells are unclear compared with SKBR-3 cells.

[0053] like Figure 1 As shown in Figure B, pyrotinib treatment significantly reduced SKBR-3 cell viability in a dose-dependent manner. 50 The tolerance of drug-resistant cells SKBR-3_PR to pyrotinib was significantly improved, IC 50 Increased to about 129.89 μM.

[0054] 3. Detection of ABCC4 expression level in pyrotinib-resistant HER2-positive breast cancer cells

[0055] Realtime-PCR and Western blot experiments were used to detect the expression changes of ABBC4 in SKBR-3 and SKBR-3_PR cells. The experimental process is as follows:

[0056] Realtime-PCR experiment:

[0057] Cells were collected and total RNA was extracted using an RNA extraction kit (purchased from Bio-Tech). TMAfter reverse transcription was completed using the RT reagent Kit (purchased from Bio-Rad Biotechnology Co., Ltd.), qPCR experiments were performed. The qPCR reaction system was provided by BeyoFast TM SYBR Green qPCR Mix (2X) (purchased from Bio-Tech) 7.5 μL, DEPC water 5.1 μL, front primer 0.45 μL (SEQ ID NO: 1), back primer 0.45 μL (SEQ ID NO: 2) and reverse transcription product 1.5 μL; qPCR reaction conditions are: denaturation 95°C, 1 min; annealing 95°C, 10 sec; extension 60°C 30 sec (40 cycles); melting curve was drawn. After the qPCR reaction was completed, the Ct value of each sample was obtained on the instrument and 2 -ΔΔCt The algorithm is used for quantitative analysis. The analysis results are shown in Figure 2 A in.

[0058] Western blot validation:

[0059] Pretreatment: Collect cells, extract total cell protein with RIPA lysis buffer (purchased from Bio-Tech), then take samples to measure protein concentration (BCA method, refer to the literature "Walker JM. The bicinchoninic acid (BCA) assay for protein quantitation. Methods Mol Biol. 1994; 32: 5-8. doi: 10.1385 / 0-89603-268-X: 5."), add SDS loading buffer to adjust the protein concentration to 2 μg / μL according to the measured results, and obtain the pretreatment sample. Heat the pretreatment sample in a metal bath at 100°C for 10 minutes to obtain the protein sample to be tested. Label the protein sample to be tested and store it in a refrigerator at 20°C for use.

[0060] SDS-PAGE: Use Western blot electrophoresis device, add fresh electrophoresis solution to the inner tank and outer tank. Add the quantitative protein sample and protein marker according to the experimental plan, connect the electrophoresis device, run at a constant voltage of 80V until the protein marker begins to separate, change the constant voltage to 120V and stop when bromophenol blue reaches the appropriate position.

[0061] Transfer (wet transfer): prepare transfer solution, transfer clips, ice and filter paper, activate PVDF membrane with methanol, gently peel off the glass plate, trim the glue according to experimental requirements, and then transfer it to the PVDF membrane. Place it on the transfer clip according to the principle of black glue and white film. The molecular weight of the target molecule ABCC4 is 220kDa, the constant current is 400mA, and the transfer time is 35 minutes.

[0062] Blocking: Mix 475 mL of double distilled water, 25 mL of 20×TBS solution and 500 μL of Tween20 to obtain TBST working solution; dissolve 5 g of skim milk powder in 50 mL of TBST working solution to obtain 5% skim milk powder blocking solution; place the wet-transferred PVDF membrane in a 5% skim milk powder solution blocking box and block at room temperature (25°C) for 1 h.

[0063] Antibody incubation and development: Use the primary antibody diluent (purchased from Beyotime) to dilute the primary antibody (purchased from Abcam, model ab180712) 1000 times to obtain the primary antibody working solution; use the primary antibody working solution to immerse the PVDF membrane and incubate at 4°C for 16 hours. After the incubation, recover the primary antibody and wash the membrane three times with TBST working solution, each for 10 minutes. Use 5% skimmed milk powder blocking solution to dilute the secondary antibody (purchased from Beyotime, model A0208) 5000 times to obtain the secondary antibody working solution; use the secondary antibody working solution to immerse the PVDF membrane and incubate at room temperature (25°C) on a shaker (150rpm) for 1 hour. After the incubation, recover the secondary antibody and wash the membrane three times with TBST working solution, each for 10 minutes. Use Millipore chemiluminescence developing reagent, evenly drop it on the PVDF membrane, and image it with time gradient.

[0064] Band gray value statistics: Image J was used for quantitative analysis of gray values; GraphPad Prism8 software was used for analysis and plotting. The analysis results are shown in Figure 2 B in.

[0065] like Figure 2 As shown in A, transcriptomics and qPCR experiments showed that the mRNA level of ABCC4 in SKBR-3_PR cells was higher than that in SKBR-3, with obvious statistical significance.

[0066] like Figure 2 As shown in B, the Western blot experiment showed that the protein level of ABCC4 in SKBR-3_PR was higher than that in SKBR-3; and after repeating the experiment three times, the statistical analysis of WB bands showed obvious statistical significance.

[0067] Therefore, ABCC4 can be used as a diagnostic indicator during the treatment of HER2-positive breast cancer patients with pyrotinib, so as to facilitate the monitoring of the therapeutic effect of pyrotinib on HER2-positive breast cancer and timely adjust the targeted treatment plan.

[0068] Experimental Example 2: Effect of ABCC4 knockdown on the proliferation of HER2-positive breast cancer resistant to pyrotinib in vitro (in vitro experiment)

[0069] 1. Determine the multiplicity of infection of the recombinant lentivirus that inhibits ABCC4

[0070] The recombinant lentivirus that inhibits ABCC4 (purchased from Santa Cruz, catalog number sc-40750-V, virus titer 2×10 8 / TUmL) to MOI (Multiplicity of infection) values ​​of 1, 10, 50, and 100 to obtain virus dilution A, virus dilution B, virus dilution C, and virus dilution D. SKBR-3_PR cells were cultured at 5×10 3 The inoculation amount of cells / well was inoculated into a 96-well plate with 100 μL of RPMI-1640 medium containing 10% (v / v) fetal bovine serum added to each well, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 hours; after culturing for 24 hours, the medium in the 96-well plate was discarded with a sterile syringe, the cells in the 96-well plate were rinsed with phosphate buffer, and ABCC4 knockdown group A, ABCC4 knockdown group B, ABCC4 knockdown group C and ABCC4 knockdown group D were set in the 96-well plate, with 2 duplicate wells for each group; after the setting was completed, 10 μL of virus diluent A, 90 μL of DMEM medium and 5 μg / mL of Polybrene (purchased from Biyuntian) were added to the wells of ABCC4 knockdown group A, and 10 μL of virus diluent B, 90 μL of DMEM medium and 5 μg / mL Polybrene, 10 μL virus dilution C, 90 μL DMEM medium and 5 μg / mL Polybrene were added to the wells of ABCC4 knockdown group C, and 10 μL virus dilution D, 90 μL DMEM medium and 5 μg / mL Polybrene were added to the wells of ABCC4 knockdown group D, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 hours; after culturing for 24 hours, the medium in the 96-well plate was discarded with a sterile syringe, the cells in the 96-well plate were rinsed with phosphate buffer, 100 μL DMEM medium was added to the wells of the four groups, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 48 hours; after culturing for 48 hours, the cell state and fluorescence intensity were observed using an inverted fluorescence microscope, and it was found that the MOI value of 50 was the highest infection efficiency group when the cell state was good, so the MOI value of 50 was selected for subsequent experiments. MOI value = virus titer × virus volume / cell number.

[0071] 2. Western Blot method to detect the knockdown efficiency of recombinant lentivirus that inhibits ABCC4

[0072] SKBR-3_PR cells were cultured at 5×10 5The inoculation amount of cells / well was inoculated into a 12-well plate with 0.5 mL of RPMI-1640 medium containing 10% (v / v) fetal bovine serum added to each well, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 hours; after culturing for 24 hours, the medium in the 12-well plate was discarded with a sterile syringe, the cells in the 12-well plate were rinsed with phosphate buffer, 0.05 mL of virus diluent C, 0.5 mL of DMEM medium and 5 μg / mL of Polybrene were added to the wells of the 12-well plate, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 hours; after culturing for 24 hours, the medium in the 12-well plate was discarded with a sterile syringe, the cells in the 12-well plate were rinsed with phosphate buffer, and 1 mL of DMEM culture medium, cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 hours; after culturing for 24 hours, the cells in the 12-well plate were digested and collected with digestion solution (purchased from Beyotime), and resuspended with 3mL DMEM culture medium to obtain a resuspension; after transferring all the resuspension into a 60mm medium-sized cell culture dish, 2.5μg / mL of puromycin (purchased from Beyotime) was added, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for screening. During the screening period, the cell status and fluorescence intensity were observed on time every day, and if the culture medium changed color, fresh culture medium should be replaced in time; after culturing for 5 days, the cells in the medium-sized cell culture dish were collected and resuspended with 3mL The cells were resuspended in DMEM medium to obtain a cell suspension; the cell suspension was inoculated into a 96-well plate by a multiple dilution method (using DMEM medium in a 10-fold gradient dilution), and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 hours; after culturing for 24 hours, the medium in the 96-well plate was discarded with a sterile syringe, the cells in the 96-well plate were rinsed with phosphate buffer, 1000 μL of DMEM medium containing 2.5 μg / mL of puromycin was added to the 96-well plate, and the plate was cultured in a 5% (v / v) CO2, 37°C cell culture incubator for screening. During the screening period, the wells with only one cell were observed under a microscope every other day and marked, and if the culture medium changed color, fresh culture medium should be replaced in time; after culturing for two weeks, the monoclonal cells found were transferred to a 12-well plate and passaged and amplified, and the protein was extracted according to the method of Experimental Example 1, and the protein level of ABCC4 was detected by Western Blot method (the test results are shown in Figure 3 A) in the figure was used to evaluate the knockdown efficiency, and the cells with the highest knockdown efficiency were selected for expansion and cryopreservation and used in subsequent experiments. The resulting cells are SKBR-3_PR / ABCC4 KD cell.

[0073] 3. Detection of the effect of ABCC4 knockdown on the proliferation of HER2-positive breast cancer resistant to pyrotinib in vitro

[0074] SKBR-3_PR cells and SKBR-3_PR / ABCC4 KD The cells were 1×10 4 The cells were inoculated with 100 μL of RPMI-1640 medium containing 10% (v / v) fetal bovine serum per well in a 96-well plate and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 h. After 24 h of culture, 100 μL of DMEM medium containing different concentrations of pyrotinib (0 μM, 3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM, 6 replicates per well) was added to the SKBR-3_PR cells and SKBR-3_PR / ABCC4 KD The cells were cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 h. After 24 h, 20 μL of MTT reagent was added to each well of the 96-well plate and incubated at 37°C in the dark for 4 h. After the incubation, the OD value of each group was detected at a wavelength of 490 nm using an enzyme marker, and the cell survival rate was calculated. The experimental results are shown in Figure 3 B in the figure; the calculation formula for cell survival rate is as follows:

[0075] Cell survival rate (%) = [(OD value of experimental group - OD value of blank group) / (OD value of control group - OD value of blank group)] × 100%.

[0076] like Figure 3 As shown in B, compared with the drug-resistant cells SKBR-3_PR (IC 50 Compared with the control group (about 121.08 μM), the sensitivity of SKBR-3_PR cells to pyrotinib increased after ABCC4 knockdown, and the IC 50 It was reduced to about 20.49 μM, which is very close to the non-resistant SKBR-3 cells. It can be seen that ABCC4 knockdown can significantly reverse the resistance activity of resistant cells to pyrotinib in vitro.

[0077] Experimental Example 3: Effect of ABCC4 knockdown on the proliferation of HER2-positive breast cancer resistant to pyrotinib in vitro (in vivo experiment)

[0078] SKBR-3_PR cells labeled with luciferase and SKBR-3_PR / ABCC4 cells labeled with luciferase KD The cells (luciferase labeling was done by Yuanjing Biotechnology) were resuspended in PBS buffer (purchased from Biyuntian) to a cell concentration of 5×10 7 / mL, and obtain SKBR-3_PR cell suspension and SKBR-3_PR / ABCC4 KDTen BALB / c-Nude mice (4-5 weeks old, weighing 18-20 g, purchased from Changzhou Cavens Laboratory Animal Co., Ltd.) were randomly divided into two groups, namely SKBR-3_PR group and SKBR-3_PR / ABCC4 group. KD After grouping, 200 μL of SKBR-3_PR cell suspension was subcutaneously inoculated into the right armpit of mice in the SKBR-3_PR group, and 200 μL of SKBR-3_PR / ABCC4 KD The cell suspension was subcutaneously inoculated into SKBR-3_PR / ABCC4 KD After the injection, the mice were placed back in the cage and marked, and the status of the mice was observed every day. 3 At the same time, the two groups of mice were gavaged with pyrotinib for 14 days, with a gavage dose of 15 mg / kg / day. Pyrotinib was dissolved in 100 μL PBS buffer and then gavaged. During the gavage period, the weight and tumor size of the mice were measured every two days. The measurement results are shown in Figure 4 B and Figure 4 C in the figure; where tumor volume = (long diameter × short diameter 2 ) / 2. After 14 days of intraperitoneal injection, mice were injected with D-luciferin potassium salt (injection dose 3 mg / mouse, D-luciferin potassium salt was dissolved in 200 μL PBS buffer before injection) and then injected with PerkinElmer Small animal in vivo imaging was used to image mice. The imaging results are shown in Figure 4 A. After 14 days of intragastric administration, mice were euthanized by carbon dioxide, and the tumors were removed and weighed, then fixed in 4% (w / v, g / 100 mL) paraformaldehyde for H&E (Haematoxylin-eosin staining) and immunohistochemical staining (IHC). Figure 4 D in the figure; the primary antibody used for immunohistochemical staining was purchased from Abcam, model ab180712, and the secondary antibody was purchased from Gene Technology (Shanghai) Co., Ltd., model GK600505.

[0079] like Figure 4 As shown in A, the same concentration of pyrotinib was administered intragastrically to SKBR-3_PR / ABCC4 KD The tumor volume of the mice in the SKBR-3_PR group was significantly smaller than that in the mice in the SKBR-3_PR group. Figure 4 As shown in Figure B, pyrotinib treatment had no effect on the weight gain of mice in each group. Figure 4 As shown in C, SKBR-3_PR / ABCC4 KD The tumor growth rate of mice in the SKBR-3_PR group was significantly lower than that of mice in the SKBR-3_PR group. Figure 4As shown in D, compared with the SKBR-3_PR group, SKBR-3_PR / ABCC4 KD The expression of Ki67, a proliferation marker, in the tumors of mice in the control group was significantly reduced, and the number of apoptotic cells was significantly increased. It can be seen that ABCC4 knockdown can significantly reverse the resistance activity of resistant cells to pyrotinib in vivo.

[0080] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. Use of an ABC transporter C4 inhibitor in the preparation of a drug for preventing and / or treating breast cancer.

2. The use according to claim 1, characterized in that The prevention and / or treatment of breast cancer includes reversing the drug resistance activity of breast cancer cells to pyrotinib.

3. The use according to claim 1 or 2, characterized in that: The breast cancer cells include HER2-positive breast cancer cells; the HER2-positive breast cancer cells include HER2-positive breast cancer cells resistant to pyrotinib.

4. The use according to any one of claims 1 to 3, characterized in that: The ABC transporter C4 inhibitor includes siRNA targeting the gene encoding ABC transporter C4, antibodies against ABC transporter C4 and / or small molecule compounds that inhibit the expression of ABC transporter C4.

5. The use according to claim 4, characterized in that The anti-ABC transporter C4 antibody includes an anti-ABC transporter C4 monoclonal antibody and / or an anti-ABC transporter C4 polyclonal antibody.

6. The use according to any one of claims 1 to 5, characterized in that: The ingredients of the drug include an ABC transporter C4 inhibitor and pyrotinib.

7. A drug for preventing and / or treating breast cancer, characterized in that: The composition of the drug comprises an ABC transporter C4 inhibitor.

8. A molecular marker for diagnosing pyrotinib resistance in breast cancer cells, characterized in that: The molecular markers include ABC transporter C4 and / or a gene encoding ABC transporter C4.

9. Use of a reagent for detecting the molecular marker according to claim 8 in a sample to be tested in the preparation of a product for diagnosing pyrotinib resistance in breast cancer cells.

10. A product for diagnosing pyrotinib resistance in breast cancer cells, characterized in that: The product comprises a reagent for detecting the molecular marker of claim 8 in a sample to be tested.

Citation Information

Patent Citations

  • Method of prognosing and predicting breast cancer recurrence, markers employed therein and kit thereof

    CN109844534A